{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:42:40Z","timestamp":1793997760472,"version":"4.8.0"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T00:00:00Z","timestamp":1649548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL157535"],"award-info":[{"award-number":["R01HL157535"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019509","name":"Southern Finance Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019509","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.atherosclerosis.2022.04.006","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T20:46:54Z","timestamp":1653079614000},"page":"53-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":176,"special_numbering":"C","title":["Non-genetic influences on lipoprotein(a) concentrations"],"prefix":"10.1016","volume":"349","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-6864","authenticated-orcid":false,"given":"Byambaa","family":"Enkhmaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib1","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib3","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1161\/ATVBAHA.118.311220","article-title":"Lp(a) [Lipoprotein(a)]-Related risk of heart failure is evident in whites but not in other racial\/ethnic groups","volume":"38","author":"Steffen","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","article-title":"Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene","volume":"349","author":"Coassin","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0021-9150(91)90247-Z","article-title":"A palm oil-enriched diet lowers serum lipoprotein(a) in normocholesterolemic volunteers","volume":"90","author":"Hornstra","year":"1991","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib6","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0022-2275(20)41404-X","article-title":"Effect of dietary cis and trans fatty acids on serum lipoprotein[a] levels in humans","volume":"33","author":"Mensink","year":"1992","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/01.ATV.18.3.441","article-title":"Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1","volume":"18","author":"Ginsberg","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib8","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/ajcn\/86.5.1611","article-title":"Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states","volume":"86","author":"Berglund","year":"2007","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib9","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/01.ATV.17.9.1657","article-title":"Plasma lipoprotein (a) levels in men and women consuming diets enriched in saturated, cis-, or trans-monounsaturated fatty acids","volume":"17","author":"Clevidence","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib10","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1093\/jn\/133.11.3422","article-title":"A diet rich in coconut oil reduces diurnal postprandial variations in circulating tissue plasminogen activator antigen and fasting lipoprotein (a) compared with a diet rich in unsaturated fat in women","volume":"133","author":"Muller","year":"2003","journal-title":"J. Nutr."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib11","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1161\/01.ATV.0000118012.64932.f4","article-title":"Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a)","volume":"24","author":"Silaste","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114859","article-title":"Healthy dietary interventions and lipoprotein(a) plasma levels: results from the Omni Heart Trial","volume":"9","author":"Haring","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib13","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1001\/jama.294.19.2455","article-title":"Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the Omni Heart randomized trial","volume":"294","author":"Appel","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib14","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1194\/jlr.M005769","article-title":"Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet","volume":"51","author":"Faghihnia","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib15","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein[a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MOL.0b013e328308b622","article-title":"The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity","volume":"19","author":"Tsimikas","year":"2008","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2022.04.001","article-title":"Oxidized phospholipid modification of lipoprotein(a): epidemiology, biochemistry and pathophysiology","volume":"349","author":"Koschinsky","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib18","first-page":"310","article-title":"Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia-a randomized controlled feeding trial","volume":"115(1)","author":"Ebbeling","year":"2022","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2014.01.049","article-title":"Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk","volume":"234","author":"Langsted","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/bmjnph-2020-000189","article-title":"Does a ketogenic diet lower a very high Lp(a)? A striking experiment in a male physician","volume":"3","author":"Scholl","year":"2020","journal-title":"BMJ Nutr. Prev. Health"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib21","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.metabol.2011.07.013","article-title":"A Mediterranean-style, low-glycemic-load diet decreases atherogenic lipoproteins and reduces lipoprotein (a) and oxidized low-density lipoprotein in women with metabolic syndrome","volume":"61","author":"Jones","year":"2012","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib22","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001355","article-title":"Effect of a moderate fat diet with and without avocados on lipoprotein particle number, size and subclasses in overweight and obese adults: a randomized, controlled trial","volume":"4","author":"Wang","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib23","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/jn\/nxz313","article-title":"Replacing saturated fats with unsaturated fats from walnuts or vegetable oils lowers atherogenic lipoprotein classes without increasing lipoprotein(a)","volume":"150","author":"Tindall","year":"2020","journal-title":"J. Nutr."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib24","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.cll.2006.07.004","article-title":"Cholesterol profile measurement by vertical auto profile method","volume":"26","author":"Kulkarni","year":"2006","journal-title":"Clin. Lab. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib25","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jacl.2016.09.012","article-title":"Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: implications for clinical practice interpretation of Lp(a)-mediated risk","volume":"10","author":"Yeang","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib26","doi-asserted-by":"crossref","first-page":"538","DOI":"10.7326\/0003-4819-132-7-200004040-00005","article-title":"Substituting walnuts for monounsaturated fat improves the serum lipid profile of hypercholesterolemic men and women. A randomized crossover trial","volume":"132","author":"Zambon","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib27","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/jn\/131.9.2275","article-title":"A monounsaturated fatty acid-rich pecan-enriched diet favorably alters the serum lipid profile of healthy men and women","volume":"131","author":"Rajaram","year":"2001","journal-title":"J. Nutr."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib28","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1161\/01.CIR.0000028421.91733.20","article-title":"Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover trial","volume":"106","author":"Jenkins","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000993","article-title":"Effects of daily almond consumption on cardiometabolic risk and abdominal adiposity in healthy adults with elevated LDL-cholesterol: a randomized controlled trial","volume":"4","author":"Berryman","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib30","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005162","article-title":"Effects of dark chocolate and almonds on cardiovascular risk factors in overweight and obese individuals: a randomized controlled-feeding trial","volume":"6","author":"Lee","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1089\/met.2016.0066","article-title":"Effect of almond supplementation on glycemia and cardiovascular risk factors in Asian Indians in North India with type 2 diabetes mellitus: a 24-week study","volume":"15","author":"Gulati","year":"2017","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148765","article-title":"Causal role of alcohol consumption in an improved lipid profile: the atherosclerosis risk in communities (ARIC) study","volume":"11","author":"Vu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib33","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/0003319714549557","article-title":"Relationship between alcohol consumption and serum lipid profiles among middle-aged population in China: a multiple-center cardiovascular epidemiological study","volume":"66","author":"Hao","year":"2015","journal-title":"Angiology"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1475-2891-12-147","article-title":"A daily glass of red wine associated with lifestyle changes independently improves blood lipids in patients with carotid arteriosclerosis: results from a randomized controlled trial","volume":"12","author":"Droste","year":"2013","journal-title":"Nutr. J."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.clnu.2012.08.022","article-title":"Effects of red wine polyphenols and alcohol on glucose metabolism and the lipid profile: a randomized clinical trial","volume":"32","author":"Chiva-Blanch","year":"2013","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib36","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3390\/nu12072024","article-title":"Diet and Lp(a): does dietary change modify residual cardiovascular risk conferred by Lp(a)?","volume":"12","author":"Enkhmaa","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0021-9150(89)90211-6","article-title":"Lipids and endurance physical activity","volume":"75","author":"Hellsten","year":"1989","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib38","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/pmed.1994.1048","article-title":"Environmental and behavioral influences on plasma lipoprotein(a) concentration in women twins","volume":"23","author":"Selby","year":"1994","journal-title":"Prev. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib39","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/00005768-199606000-00011","article-title":"Physical activity, lipids, apolipoproteins, and Lp(a) in the Northern Ireland health and activity survey","volume":"28","author":"MacAuley","year":"1996","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib40","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1249\/00005768-199404000-00005","article-title":"Relationship between cardiorespiratory fitness and lipoprotein(a) in men and women","volume":"26","author":"Israel","year":"1994","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib41","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0026-0495(96)90126-2","article-title":"Factors affecting fibrinolytic potential: cardiovascular fitness, body composition, and lipoprotein(a)","volume":"45","author":"Szymanski","year":"1996","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib42","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/bjsm.27.4.271","article-title":"Plasma lipid, lipoprotein and apolipoprotein profiles in Nigerian university athletes and non-athletes","volume":"27","author":"Oyelola","year":"1993","journal-title":"Br. J. Sports Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib43","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1249\/00005768-199504000-00005","article-title":"Lipoprotein(a) [Lp(a)] levels in middle-aged male runners and sedentary controls","volume":"27","author":"Hubinger","year":"1995","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib44","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/00005768-199608000-00004","article-title":"Lipoprotein(a) in endurance athletes, power athletes, and sedentary controls","volume":"28","author":"Halle","year":"1996","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib45","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0002-9378(11)90604-8","article-title":"Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise, and estrogen","volume":"166","author":"Lobo","year":"1992","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00005768-199606000-00015","article-title":"The effect of endurance training on lipoprotein(a) [Lp(a)] levels in middle-aged males","volume":"28","author":"Hubinger","year":"1996","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib47","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00005768-199704000-00003","article-title":"Acute effects of treadmill running on lipoprotein(a) levels in males and females","volume":"29","author":"Hubinger","year":"1997","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib48","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/01.CIR.89.3.975","article-title":"Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP)","volume":"89","author":"Haskell","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/15438627.2016.1191488","article-title":"Aerobic, resistance and combined training and detraining on body composition, muscle strength, lipid profile and inflammation in coronary artery disease patients","volume":"24","author":"Theodorou","year":"2016","journal-title":"Res. Sports Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib50","first-page":"506","article-title":"Effect of long-term physical activity on PCSK9, high- and low-density lipoprotein cholesterol, and lipoprotein(a) levels: a prospective observational trial","volume":"127","author":"Sponder","year":"2017","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib51","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1651-2227.1994.tb13009.x","article-title":"Lipoprotein (a) levels in children and young adults: the influence of physical activity. The Cardiovascular Risk in Young Finns Study","volume":"83","author":"Taimela","year":"1994","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib52","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2337\/diacare.16.2.421","article-title":"The relationship of physical fitness to lipid and lipoprotein(a) levels in adolescents with IDDM","volume":"16","author":"Austin","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0009-3084(94)90140-6","article-title":"Long distance runners and body-builders exhibit elevated plasma levels of lipoprotein(a)","volume":"67\u201368","author":"Cardoso","year":"1994","journal-title":"Chem. Phys. Lipids"},{"issue":"Pt 2","key":"10.1016\/j.atherosclerosis.2022.04.006_bib54","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/000456329503200208","article-title":"Long-term physical exercise and lipoprotein(a) levels in a previously sedentary male and female population","volume":"32","author":"Ponjee","year":"1995","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib55","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0026-0495(00)80041-4","article-title":"Effect of physical exercise on lipoprotein(a) and low-density lipoprotein modifications in type 1 and type 2 diabetic patients","volume":"49","author":"Rigla","year":"2000","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib56","article-title":"Associations of low-intensity resistance training with body composition and lipid profile in obese patients with type 2 diabetes","volume":"10","author":"Hamasaki","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib57","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacl.2017.10.024","article-title":"Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials","volume":"12","author":"Marcovina","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib58","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/01.ATV.5.3.265","article-title":"Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B","volume":"5","author":"Guyton","year":"1985","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib59","first-page":"2071","article-title":"[Plasma concentration of lipoprotein(a) and distribution of its subtypes in the healthy population of Hungary]","volume":"131","author":"Csaszar","year":"1990","journal-title":"Orv. Hetil."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib60","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0022-2275(20)41895-4","article-title":"Contribution of the apo[a] phenotype to plasma Lp[a] concentrations shows considerable ethnic variation","volume":"32","author":"Helmhold","year":"1991","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib61","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/01.CIR.87.4.1135","article-title":"Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study","volume":"87","author":"Jenner","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib62","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/oxfordjournals.aje.a116517","article-title":"Serum lipoprotein(a) levels in racially different populations","volume":"136","author":"Cobbaert","year":"1992","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib63","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/ije\/23.1.20","article-title":"Comparison of serum lipoprotein(a) distribution and its correlates among black and white populations","volume":"23","author":"Bovet","year":"1994","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib64","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.amjcard.2010.01.370","article-title":"Lipoprotein(a), inflammation, and peripheral arterial disease in a community-based sample of older men and women (the InCHIANTI study)","volume":"105","author":"Volpato","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib65","first-page":"160","article-title":"Racial (black-white) differences in serum lipoprotein (a) distribution and its relation to parental myocardial infarction in children","volume":"84","author":"Srinivasan","year":"1991","journal-title":"Bogalusa Heart Stud., Circ."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib66","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1515\/CCLM.2011.645","article-title":"Determinants of blood levels of some thrombogenic biomarkers in healthy Arab adolescent subjects","volume":"49","author":"Akanji","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib67","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/oxfordjournals.aje.a117516","article-title":"Lipoprotein(a) levels in the Japanese population: influence of age and sex, and relation to atherosclerotic risk factors. The Jichi Medical School Cohort Study","volume":"141","author":"Nago","year":"1995","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib68","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2459\/JCM.0b013e328346d367","article-title":"Lipoprotein(a) concentration does not differ between sexes in healthy offspring of patients with premature myocardial infarction","volume":"12","author":"Barra","year":"2011","journal-title":"J. Cardiovasc. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib69","doi-asserted-by":"crossref","first-page":"481","DOI":"10.33549\/physiolres.930511","article-title":"Gender differences in plasma levels of lipoprotein (a) in patients with angiographically proven coronary artery disease","volume":"53","author":"Frohlich","year":"2004","journal-title":"Physiol. Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib70","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1476-511X-13-65","article-title":"Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort","volume":"13","author":"Allard","year":"2014","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib71","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.atherosclerosis.2011.02.007","article-title":"Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia","volume":"216","author":"Nenseter","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib72","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2022.04.002","article-title":"Recent advances in demystifying the metabolism of lipoprotein(a)","volume":"349","author":"Chemello","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib73","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/0003319719854872","article-title":"Lipoprotein (a) and 10-year cardiovascular disease incidence in apparently healthy individuals: a sex-based sensitivity analysis from ATTICA cohort study","volume":"70","author":"Kouvari","year":"2019","journal-title":"Angiology"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib74","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/ATVBAHA.118.310865","article-title":"Genetic factors explain a major fraction of the 50% lower lipoprotein(a) concentrations in Finns","volume":"38","author":"Erhart","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib75","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12933-021-01363-x","article-title":"Association of sex-specific differences in lipoprotein(a) concentrations with cardiovascular mortality in individuals with type 2 diabetes mellitus","volume":"20","author":"Markus","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib76","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: New insights from a large National Biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib77","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.atherosclerosis.2022.04.016","article-title":"Lp(a) and diabetes mellitus","volume":"349","author":"Lamina","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib78","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/oxfordjournals.aje.a116571","article-title":"Lipoprotein(a) concentrations in Mexican Americans and non-Hispanic whites: the san Antonio heart study","volume":"136","author":"Haffner","year":"1992","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib79","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0021-9150(95)05756-0","article-title":"Testosterone-induced suppression of lipoprotein(a) in normal men; relation to basal lipoprotein(a) level","volume":"122","author":"Marcovina","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib80","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1055\/s-2007-1001768","article-title":"Correlation between plasma lipoprotein Lp(a) and sex hormone concentrations: a cross-sectional study in healthy males","volume":"26","author":"Denti","year":"1994","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib81","first-page":"362","article-title":"The relationship between level of androgenic hormones and coronary artery disease in men","volume":"18","author":"Davoodi","year":"2007","journal-title":"Cardiovasc. J. Afr."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib82","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.0001-6349.2004.00417.x","article-title":"The association of androgenic sex steroids with serum lipid levels in postmenopausal women","volume":"83","author":"Noyan","year":"2004","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib83","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1530\/eje.1.02167","article-title":"Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women","volume":"154","author":"Lambrinoudaki","year":"2006","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib84","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0010-7824(95)00136-0","article-title":"Effect of testosterone enanthate on serum lipoproteins in man","volume":"52","author":"Anderson","year":"1995","journal-title":"Contraception"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib85","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S0002-9149(96)00174-9","article-title":"Testosterone decreases lipoprotein(a) in men","volume":"77","author":"Zmunda","year":"1996","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib86","first-page":"2633","article-title":"Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males","volume":"81","author":"Berglund","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib87","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.fertnstert.2005.12.039","article-title":"Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women","volume":"86","author":"Zang","year":"2006","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib88","first-page":"3372","article-title":"Effects of gonadotropin and testosterone treatments on Lipoprotein(a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism","volume":"81","author":"Ozata","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib89","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0378-5122(03)00246-9","article-title":"Serum lipids in oophorectomized women during estrogen and testosterone replacement therapy","volume":"47","author":"Floter","year":"2004","journal-title":"Maturitas"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib90","first-page":"3896","article-title":"The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life","volume":"84","author":"Barnhart","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib91","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0005-2760(84)90078-X","article-title":"Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol","volume":"795","author":"Albers","year":"1984","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib92","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0021-9150(92)90008-5","article-title":"Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid","volume":"92","author":"Crook","year":"1992","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib93","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0272-6386(97)90340-1","article-title":"Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients","volume":"29","author":"Teruel","year":"1997","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib94","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00005768-199602000-00004","article-title":"Lipoprotein (a) and cholesterol in body builders using anabolic androgenic steroids","volume":"28","author":"Cohen","year":"1996","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib95","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0021-9150(01)00519-6","article-title":"Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle size and lipoprotein(a) in men","volume":"159","author":"Hislop","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib96","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bjsm.2003.000199","article-title":"Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein(a)","volume":"38","author":"Hartgens","year":"2004","journal-title":"Br. J. Sports Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib97","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/bmj.303.6804.694","article-title":"Lipoprotein (a) concentrations in postmenopausal women taking norethisterone","volume":"303","author":"Farish","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib98","first-page":"837","article-title":"Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein[a]","volume":"123","author":"Mendoza","year":"1994","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib99","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1161\/01.ATV.14.10.1586","article-title":"Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women","volume":"14","author":"Shewmon","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib100","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1161\/01.ATV.14.2.275","article-title":"Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women","volume":"14","author":"Kim","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib101","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1001\/archinte.1996.00440140123012","article-title":"Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy","volume":"156","author":"Kim","year":"1996","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib102","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jacc.2008.04.009","article-title":"Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events","volume":"52","author":"Suk Danik","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib103","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1463-1326.2005.00545.x","article-title":"Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women","volume":"8","author":"Salpeter","year":"2006","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib104","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1055\/s-2006-950504","article-title":"Serum lipoprotein(a) dynamics before\/after menopause and long-term effects of hormone replacement therapy on lipoprotein(a) levels in middle-aged and older Japanese women","volume":"38","author":"Ushioda","year":"2006","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000211676","article-title":"Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause","volume":"68","author":"Perrone","year":"2009","journal-title":"Gynecol. Obstet. Invest."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib106","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.maturitas.2017.02.009","article-title":"The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: a systematic review and meta-analysis","volume":"99","author":"Anagnostis","year":"2017","journal-title":"Maturitas"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib107","doi-asserted-by":"crossref","first-page":"dgaa672","DOI":"10.1210\/clinem\/dgaa672","article-title":"Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis","volume":"105","author":"Kotwal","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib108","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0905633","article-title":"Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia","volume":"362","author":"Ladenson","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib109","first-page":"455","article-title":"Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study, the Lancet","volume":"2","author":"Sjouke","year":"2014","journal-title":"Diab. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib110","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12261","article-title":"Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome","volume":"277","author":"Angelin","year":"2015","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib111","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1194\/jlr.M051664","article-title":"Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans","volume":"55","author":"Bonde","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib112","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1089\/thy.2020.0071","article-title":"Thyroid hormone analogues: an update","volume":"30","author":"Zucchi","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib113","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ando.2014.06.002","article-title":"Effects of levothyroxine treatment on insulin sensitivity, endothelial function and risk factors of atherosclerosis in hypothyroid women","volume":"75","author":"Deyneli","year":"2014","journal-title":"Ann. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib114","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/thy.2017.0330","article-title":"Effects of thyrotropin on peripheral thyroid hormone metabolism and serum lipids","volume":"28","author":"Beukhof","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib115","article-title":"The lipid parameters and lipoprotein(a) excess in Hashimoto thyroiditis","volume":"2015","author":"Yetkin","year":"2015","journal-title":"Internet J. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib116","article-title":"A study of the extended lipid profile including oxidized LDL, small dense LDL, lipoprotein (a) and apolipoproteins in the assessment of cardiovascular risk in hypothyroid patients","volume":"10","author":"Bansal","year":"2016","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib117","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5455\/medarh.2021.75.11-15","article-title":"Changes of certain metabolic and cardiovascular markers Fructosamine, H-FABP and lipoprotein (a) in patients with hypothyroidism","volume":"75","author":"Kaftan","year":"2021","journal-title":"Med. Arch."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib118","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/01.ATV.13.2.296","article-title":"Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations","volume":"13","author":"Eden","year":"1993","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib119","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1530\/eje.0.1370459","article-title":"The effect of recombinant human GH replacement therapy on lipoprotein(a) and other lipid parameters in adults with acquired GH deficiency: results of a double-blind and placebo-controlled trial","volume":"137","author":"Nolte","year":"1997","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib120","doi-asserted-by":"crossref","first-page":"101393","DOI":"10.1016\/j.ghir.2021.101393","article-title":"Growth hormone replacement may influence the biological action of thyroid hormone on liver and bone tissue","volume":"57\u201358","author":"Glynn","year":"2021","journal-title":"Growth Hormone IGF Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib121","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116213","article-title":"Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a)","volume":"91","author":"Dieplinger","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib122","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0272-6386(99)70147-2","article-title":"Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure","volume":"33","author":"Milionis","year":"1999","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib123","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1046\/j.1523-1755.1998.00880.x","article-title":"Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure","volume":"53","author":"Stenvinkel","year":"1998","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib124","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1681\/ASN.V111105","article-title":"Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure","volume":"11","author":"Kronenberg","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib125","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and consequences of lipoprotein(a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib126","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1681\/ASN.V61110","article-title":"Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis","volume":"6","author":"Kronenberg","year":"1995","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib127","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1046\/j.1523-1755.1999.00273.x","article-title":"Inflammation enhances cardiovascular risk and mortality in hemodialysis patients","volume":"55","author":"Zimmermann","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.atherosclerosis.2022.04.004","article-title":"Lipoprotein(a): an underestimated inflammatory mastermind","volume":"349","author":"Dzobo","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib129","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1093\/ndt\/gfq027","article-title":"Impact of peritoneal transport characteristics on cardiac function in paediatric peritoneal dialysis patients: a Turkish Pediatric Peritoneal Dialysis Study Group (TUPEPD) report","volume":"25","author":"Bakkaloglu","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib130","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.ajkd.2004.08.043","article-title":"Factors associated with lipoprotein(a) in chronic kidney disease","volume":"45","author":"Uhlig","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib131","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/nep.12792","article-title":"Live donor study - implications of kidney donation on cardiovascular risk with a focus on lipid parameters including lipoprotein a","volume":"21","author":"Doucet","year":"2016","journal-title":"Nephrology"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib132","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/sj.ki.5002131","article-title":"In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients","volume":"71","author":"Frischmann","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(96)90026-8","article-title":"Lipoprotein(a) in renal disease","volume":"27","author":"Kronenberg","year":"1996","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib134","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-119-4-199308150-00002","article-title":"Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome","volume":"119","author":"Wanner","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib135","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1523-1755.2004.00418.x","article-title":"The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome","volume":"65","author":"Kronenberg","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib136","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000188426","article-title":"Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome","volume":"69","author":"Hong","year":"1995","journal-title":"Nephron"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib137","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/clinchem\/41.6.908","article-title":"Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria","volume":"41","author":"Joven","year":"1995","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib138","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.V981474","article-title":"Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome","volume":"9","author":"De Sain-Van Der Velden","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib139","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein(a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib140","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1161\/01.ATV.14.9.1399","article-title":"Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation","volume":"14","author":"Kronenberg","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib141","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.ejhg.5201016","article-title":"Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation","volume":"11","author":"Kronenberg","year":"2003","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib142","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0021-9150(99)00014-3","article-title":"Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up","volume":"144","author":"Kerschdorfer","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib143","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000112225","article-title":"Effects of renal replacement therapy on plasma lipoprotein(a) levels","volume":"28","author":"Rosas","year":"2008","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib144","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000168361","article-title":"Elevated lipoprotein(a) levels in renal transplantation and hemodialysis patients","volume":"11","author":"Heimann","year":"1991","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib145","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1445-5994.1992.tb02119.x","article-title":"Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation","volume":"22","author":"Irish","year":"1992","journal-title":"Aust. N. Z. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib146","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1161\/01.ATV.14.9.1393","volume":"14","author":"Azrolan","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib147","first-page":"863","article-title":"Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy","volume":"8","author":"Brown","year":"1993","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib148","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1159\/000187400","article-title":"Lipoprotein (a) levels in end-stage renal failure and renal transplantation","volume":"64","author":"Barbagallo","year":"1993","journal-title":"Nephron"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib149","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1432-2277.1996.tb00883.x","article-title":"Factors influencing plasma lipid profiles including lipoprotein (a) concentrations in renal transplant recipients","volume":"9","author":"Wheeler","year":"1996","journal-title":"Transpl. Int."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib150","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0140-6736(93)92616-2","article-title":"Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients?","volume":"341","author":"Webb","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib151","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1681\/ASN.V5122073","article-title":"The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients","volume":"5","author":"Hilbrands","year":"1995","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib152","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000189549","article-title":"Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation","volume":"75","author":"Brown","year":"1997","journal-title":"Nephron"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib153","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0140-6736(93)90546-S","article-title":"Cyclosporin and serum lipids in renal transplant recipients","volume":"341","author":"Kronenberg","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib154","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0021-9150(95)05552-8","article-title":"Effect of immunosuppressive drug regime on cardiovascular risk profile following kidney transplantation","volume":"116","author":"Murphy","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib155","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.V1251052","article-title":"Impact of apolipoprotein(a) phenotypes on long-term renal transplant survival","volume":"12","author":"Wahn","year":"2001","journal-title":"J. Am. Soc. Nephrol. : JASN (J. Am. Soc. Nephrol.)"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib156","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein(a): impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib157","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/0149-2918(95)80048-4","article-title":"Lipoprotein(a) concentration in patients with chronic active hepatitis C before and after interferon treatment","volume":"17","author":"Malaguarnera","year":"1995","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib158","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0021-9150(94)90006-X","article-title":"Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis","volume":"105","author":"Gregory","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib159","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1476-511X-7-25","article-title":"Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases","volume":"7","author":"Jiang","year":"2008","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib160","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0009-8981(94)90178-3","article-title":"Relationship between lipoprotein(a) levels in serum and some indices of protein synthesis in liver cirrhosis","volume":"224","author":"Alessandri","year":"1994","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib161","first-page":"542","article-title":"Serum lipoprotein (a) levels in liver diseases caused by hepatitis","volume":"120","author":"Irshad","year":"2004","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib162","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.510240602","article-title":"Low lipoprotein(a) levels during acute viral hepatitis","volume":"24","author":"Geiss","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib163","first-page":"898","article-title":"Correlation of serum HCV core concentration with blood level of lipid and antioxidants in various forms of liver diseases","volume":"54","author":"Irshad","year":"2007","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib164","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5604\/01.3001.0010.7536","article-title":"Worsening of serum lipid profile after direct acting antiviral treatment","volume":"17","author":"Gitto","year":"2018","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib165","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00004836-200308000-00017","article-title":"Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis","volume":"37","author":"Koruk","year":"2003","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib166","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cca.2016.07.003","article-title":"Association between lipoprotein(a) and nonalcoholic fatty liver disease among Korean adults","volume":"461","author":"Nam","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib167","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.07.020","article-title":"Serum lipoprotein(a) levels and insulin resistance have opposite effects on fatty liver disease","volume":"308","author":"Jung","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib168","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2020.02.026","article-title":"Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor","volume":"299","author":"Konishi","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib169","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12944-020-01310-x","article-title":"Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study","volume":"19","author":"Zhang","year":"2020","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253298","article-title":"Significantly higher atherosclerosis risks in patients with obstructive sleep apnea and non-alcoholic fatty liver disease","volume":"16","author":"Sukahri","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2022.04.006_bib171","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: are we making a mountain out of a Molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022001836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022001836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:53:07Z","timestamp":1758156787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915022001836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":171,"alternative-id":["S0021915022001836"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.006","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-genetic influences on lipoprotein(a) concentrations","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}